BioNTech to close three German plants after failing to find buyers

BioNTech will close three German production sites in Idar-Oberstein, Marburg and Tübingen after failing to find buyers, affecting about 1,800 employees; the company also plans to shut its Singapore facility. The German sites are scheduled to close between late 2027 and late 2028, and BioNTech says market and investment conditions thwarted the sale effort. The closures reflect the company’s move away from pandemic-era vaccine production amid weaker COVID-19 vaccine demand, cost-cutting and a growing focus on cancer medicines. BioNTech and employee representatives have agreed on additional severance terms, but the company has not disclosed details.